Regional Health is involved in breast cancer research trials. Below is more information about the purpose and who the physician (principal investigator) is for each trial. For more in-depth information on the research studies, click the blue name which will lead you to the U.S. National Institute of Health website or call (605) 755-2300.
A011502
A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin As Adjuvant Therapy For Node Positive HER2 Negative Breast Cancer: The ABC Trial
| To learn more, contact: Regional Health John T. Vucurevich Cancer Care Institute (605) 755-2300 |
Principal Investigators
Michael Robinson, MD Medical Oncology |
BR003
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node NegativeTriple Negative Invasive Cancer
| To learn more, contact: Regional Health John T. Vucurevich Cancer Care Institute (605) 755-2300 |
Principal Investigators
 Michael Robinson, MD Medical Oncology |
PALLAS AFT-05
PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
| To learn more, contact: Regional Health John T. Vucurevich Cancer Care Institute (605) 755-2300 |
Principal Investigators
Michael Robinson, MD Medical Oncology |
S1207
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High- Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer e3Breast Cancer Study- evaluating everolimus with endocrine therapy
| To learn more, contact: Regional Health John T. Vucurevich Cancer Care Institute (605) 755-2300 |
Principal Investigators
Michael Robinson, MD Medical Oncology |
RU011201I (BOLD303)
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer (Eisai protocol #7389-A001- 303)
| To learn more, contact: Regional Health John T. Vucurevich Cancer Care Institute (605) 755-2300 |
Principal Investigators
Michael Robinson, MD Medical Oncology |